Pharmaceutical TechnologyOriginal article
CAR-T specialist Caribou culls pipeline and seeks exit deal
Negative
AI Analysis
Summary
Caribou, a CAR-T specialist, is culling its pipeline and seeking an exit deal as the sector shifts focus toward in vivo CAR-T approaches. The company faces strategic challenges despite its origins in Nobel Prize-winning technology.
Importance:6/10
Sentiment:
-0.70
CAR-Tpipeline reductionstrategic exitsector shiftin vivo CAR-T
Related Companies
Read the original article
Published by Pharmaceutical Technology on October 7, 2026 2:16 PM
